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Dural arteriovenous fistulas 
with direct cortical venous 
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ABSTRACT
Dural arteriovenous fistulas (DAVFs) may have aggressive symptoms, especially if there 
is direct cortical venous drainage. We report our preliminary experience in transarterial 
embolization of DAVFs with direct cortical venous drainage (CVR) using Onyx®. Method: 
Nine patients with DAVFs with direct cortical venous drainage were treated: eight type 
IV and one type III (Cognard). Treatment consisted of transarterial embolization using 
Onyx-18®. Immediate post treatment angiographies, clinical outcome and late follow-up 
angiographies were studied. Results: Complete occlusion of the fistula was achieved in 
all patients with only one procedure and injection in only one arterial pedicle. On follow-
up, eight patients became free from symptoms, one improved and no one deteriorated. 
Late angiographies showed no evidence of recurrent DAVF. Conclusion: We recommend 
that transarterial Onyx® embolization of DAVFs with direct cortical venous drainage be 
considered as a treatment option, while it showed to be feasible, safe and effective.
Key words: dural arteriovenous fistula, dural arteriovenous malformation, embolization, 
endovascular, Onyx®, transarterial.
Fístulas arteriovenosas durais com drenagem cortical direta tratadas com Onyx®: 
casuística
RESUMO
As fistulas arteriovenosas durais (FAVDs) podem se manifestar com sintomas agressivos, 
especialmente se existe drenagem cortical direta. Relatamos nossa experiência preliminar 
na embolização transarterial de FAVDs com drenagem cortical direta usando Onyx®. 
Método: Nove pacientes com FAVDs com drenagem cortical direta foram tratados: oito 
do tipo IV e uma do tipo III (Cognard). O tratamento consistiu na embolização transarterial 
usando Onyx-18®. Angiografias imediatas pós-tratamento, evolução clínica e angiografias 
de controle tardias foram estudadas. Resultados: A oclusão completa da fístula foi 
alcançada em todos pacientes através de um só procedimento e injeção em apenas um 
pedículo arterial. No seguimento, oito pacientes ficaram livres de sintomas, um melhorou 
e nenhum deteriorou. Angiografias tardias de controle não mostraram evidência de FAVD 
recorrente. Conclusão: Nós recomendamos que a embolização transarterial com Onyx® 
das FAVDs com drenagem cortical direta, seja considerada como uma opção terapêutica, 
uma vez que mostrou ser factível, segura e efetiva.
Palavras-chave: fistula arteriovenosa dural, malformação arteriovenosa dural, embolização, 
endovascular, Onyx®, transarterial.
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Intracranial dural arteriovenous fistulas (DAVFs) are 
considered an acquired abnormality, characterized by ab-
normal shunting of blood inside the dura between the 
arterial and the venous systems. The true incidence of 
DAVFs is difficult to determine. Earlier case series report-
ed from large single tertiary academic centers estimated 
that DAVFs represented only 10% to 15% of all cerebral ar-
teriovenous malformations diagnosed with angiography1.
There are numerous classification schemes for DAVFs 
dating back to the initial scheme proposed by Djindji-
an and Merland in 1978.2 The most useful and mod-
ern are the revised Djindjian classification proposed by 
Cognard et al.3 and the classification proposed by Bor-
den et al.4, both of which are based on the initial scheme. 
Cognard defined five types of DAVFs based exclusively 
upon the pattern of venous outflow: type I, located in the 
main sinus, with antegrade flow; type II, in the main si-
nus, with reflux into the sinus (IIa), cortical veins (Ilb), or 
both (IIa+b); type III, with direct cortical venous drainage 
without venous ectasia; type IV, with direct cortical ve-
nous drainage with venous ectasia; and type V, with spi-
nal venous drainage. No matter the classification system, 
they all focus on the patterns of venous drainage. 
DAVFs draining retrogradely into cortical veins ex-
hibit a much higher incidence of hemorrhage or venous 
infarction5. The annual mortality rate for cortical venous 
reflux may be as high as 10.4%, whereas the annual risk 
for hemorrhage or nonhemorrhagic neurologic deficits 
during follow-up are 8.1% and 6.9%, respectively, result-
ing in an annual event rate of 15%5.
We present our experience in endovascular emboliza-
tion of intracranial DAVFs with direct cortical venous drain-
age using transarterial ethylene vinyl alcohol (Onyx-18®).
METHOD
From October 2005 to May 2009, 9 consecutive previ-
ously untreated patients with intracranial DAVFs with di-
rect cortical venous drainage (Cognard types III-IV) un-
derwent endovascular treatment with Onyx-18® at three 
different institutions. There were 7 (77.7%) men and 2 
women. The mean age of these patients was 50.77±12.26 
years (median, 52 years; range 31-71 years) (Table). Clin-
ical presentation included intracranial hemorrhage in 5 
patients (55.5%), ocular symptoms in 2 (22.2%), focal neu-
rological deficit in 1 (11.1%), seizures in 1 and pulsatile 
tinnitus in 1. Symptoms were developed in an acute fash-
ion in six patients and chronic in three patients (mean 
duration, 50 months; range 6-96 months). Patients were 
questioned about medical history to identify etiologic fac-
tors such as thrombophlebitis, otitis or sinusitis, crani-
al trauma, neurosurgery, or phlebitis of the lower limb. 
None patient presented these conditions. 
Three (33.3%) DAVFs were located at the dural con-
vexity, 3 (33,3%) at the tentorial region, 2 at the anteri-
or fossa and one (11.1%) at the lesser sphenoid wing. Ac-
cording to San Millan-Ruiz et al.6 DAVFs located at the 
lesser sphenoid wing region can be classified according 
to the involvement of either the superficial middle cere-
bral vein or the lesser sphenoid wing sinus. Only one pa-
tient at our study presented a DAVF located at the lesser 
sphenoid wing region. The fistula was drained by super-
ficial middle cerebral vein. Picard et al.7 divided the ve-
nous tributaries in the tentorium into three regions: the 
lateral tentorial sinus group lie adjacent to the lateral si-
nus and receive supratentorial drainage from the lateral 
and inferior surfaces of the temporal and occipital lobes. 
The medial tentorial sinus group are situated adjacent to 
the torcula and drain into it or the lateral or straight si-
nus. They primarily receive infratentorial venous drainage 
from the cerebellar hemispheres and vermis. Finally, le-
sions along the free edge of the tentorium, which receive 
venous drainage from the basilar and lateral mesenceph-
alic veins and may have infra or supratentorial drainage or 
even drain into spinal veins (Cognard Type V). Three pa-
tients presented DAVFs located at the tentorial region. All 
of them drained primarily to cortical cerebellar veins, cor-
tical occipital veins or to the lateral pontomesencephalic 
vein. There was an average of 2.66±1.11 arterial feeders 
for each DAVF (median, 3; range, 1-5). The middle men-
ingeal artery was involved in 7 cases (77.7%), combined or 
isolated, the occipital artery in 3 and the ophthalmic ar-
tery in 3. Eight (88.8%) lesions were classified as Cognard 
IV and one (11.1%) lesion as Cognard III. Onyx injection 
was used as the single treatment modality in all cases.
An immediate post-treatment angiogram was per-
formed in all patients. Follow-up angiography was ob-
tained 6 months after the initial treatment.
Endovascular procedure
The interventions were performed under general an-
esthesia. An intravenous bolus of 3,000 UI of heparin was 
given at the beginning of the procedure. Vascular access 
was obtained via the right common femoral artery. A 
complete cerebral angiogram including both internal ca-
rotid arteries, both external carotid arteries and ipsilat-
eral vertebral artery was performed before the treatment 
to determine the DAVF angioarchitecture. A 6F guiding 
catheter was placed into the parent artery. A microcathe-
ter (Ultraflow, Micro Therapeutics, Irvine, Calif.) was ad-
vanced over a 0.008-inch microguidewire (Mirage, Mi-
cro Therapeutics) into the meningeal branch responsi-
ble for the DAVF supply, always trying to reach the fistu-
lous zone as close as possible or at least wedged into po-
sition. The microcatheter was flushed with dimethyl sul-
foxide (DMSO) and the dead space was filled with Onyx-
18® for 40 seconds. Under continuous subtraction fluoros-
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copy, very slow Onyx® injections were performed, avoid-
ing excessive reflux. 
Each treatment consisted of a single Onyx® injection, 
after one unique feeder catheterization. One patient de-
manded a direct access through a small temporal cran-
iotomy to the right middle meningeal artery because of 
difficult endovascular navigation (the middle meningeal 
artery originated from ophthalmic artery).
RESULTS
Immediate post-treatment angiographic results
Complete angiographic occlusion with anatomical ex-
clusion of the fistula was achieved in all patients, with iso-
lated arterial Onyx® injection, after one procedure, dem-
onstrated on angiography performed immediately after 
the intervention.
All Onyx® injections were performed via a meninge-
al branch. The volume of Onyx® injected ranged from 1.3 
to 3.5 mL per procedure (mean, 2.03 mL). The duration 
of the injection per pedicule ranged from 31 to 47 min-
utes, with a mean of 38 minutes.
All patients complained of headache in the first days 
after embolization that resolved with a short course of 
corticosteroids. No catheter was glued. No complication 
was observed.
Follow-up
Patients were followed-up in a period ranging from 5 
to 20 months after intervention. After treatment, 8 (88.8%) 
patients were free from symptoms related to the DAVF 
and 1 (11.1%) patient improved. No patient deteriorated.
Control angiographies after 6 months of the treatment 
showed no evidence of residual or recurrent DAVF in 
any patient.
DISCUSSION
The main goal of the treatment of type III/IV DAVFs is 
to eliminate the cortical venous drainage and the resulting 
risks. Optimal treatment aims at occluding the origin of the 
draining vein. Many options have been used: surgery8-10, 
transvenous11, or transarterial embolization12-14.
Arterial feeder ligation is not an effective treatment 
because it frequently leads to recruitment of an exten-
sive collateral network10,14.
One option is surgical clipping of the draining vein, 
especially if it is unique and easily approached8-10.
Transvenous endovascular approach consists of ret-
rograde catheterization and sacrifice of the involved ve-
nous structure15,16. For DAVFs with direct CVR (types III-
IV), dural sinus occlusion is not an option. Retrograde 
catheterization of the cortical vein draining the DAVF 
and its occlusion was performed in a few cases11. This 
is very difficult and risky, with severe complications, in-
cluding vessel rupture or perforation, venous infarct and 
hemorrhage10,17.
Since the initial description of therapeutic emboliza-
tion of DAVFs in the early 1970s18, various embolic agents 
such as particles, liquid silicone, ethyl alcohol, platinun 
microcoils and cyano-acrylates have been used by tran-
sarterial approach. Polyvinyl alcohol particles (PVA) are 
easy to handle but they often promote proximal occlu-
sion. Reduction of the shunting flow can be obtained but 
obliteration of the shunt itself is rather difficult. DAVFs 
treated with PVA frequently recanalize12,13. The use of this 
temporary embolic suspension was supplanted by liquid 
embolic embolization. It is generally accepted that reca-
nalization rate is lower with cyano-acrylate liquid adhe-
sives. The possibility of reaching the site of fistulous com-
munication is greater. Complete cure is achieved when 
all veins exiting the DAVF are occluded14. The use of N-
butyl-cyano-acrylate (NBCA) necessitates experience in 
both its preparation and delivery. Because of some chem-
ical and physical properties such polymerization rate, 
binding and viscosity, its effects are not always predict-
able, at times producing proximal feeder occlusion or ve-
nous obstruction even in normal territories19. Sometimes 
NBCA may not traverse the fistulous connection into 
the venous side permitting the re-appearance of small-
er collaterals, which may be more difficult to catheterize 
selectively.
In 2007, van Rooij et al.20, published the experience 
of their group in the management of DAFVs with CVR. 
Surgery was the treatment of choice for anterior fos-
sa DAVFs. For all other DAVFs, embolization with glue 
was the first treatment option, with the aim of complete 
cure. Five patients with an anterior fossa DAVF under-
went successful surgery. In 14 patients, the DAVF was 
completely occluded with embolization alone, and in 7 
patients, embolization was followed by surgery. Com-
plete occlusion was angiographically confirmed in 28 of 
29 DAVFs. There were no complications of surgery; em-
bolization was complicated by postembolization hemor-
rhage in 1 patient (3%). In a series of 21 DAVFs (9 type 
III-IV Cognard) treated transarterially under flow-arrest 
conditions, cures were demonstrated in all fistulae with-
out complications.14 Although the definite curative em-
bolization occurred under flow-arrest conditions, a sig-
nificant portion of these patients underwent adjunctive 
embolization with polyvinyl alcohol or NBCA or previ-
ous transvenous coiling of the recipient venous structure. 
This served to devascularize the collateral inflow to mini-
mize NBCA fragmentation, prevent systemic venous em-
bolization, and increase the probability of polymerization 
within the pathologic shunt itself. 
These studies illustrate the complex angioarchitectur-
al spectrum of DAVFs and the expertise in multimodal-
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ity treatments required to engender treatment safe and 
effective.
Ethylene vinyl alcohol (Onyx®), a polymer which is 
dissolved in DMSO, is an alternative embolic agent. In 
comparison with NBCA, Onyx does not polymerize but 
the copolymer precipitates as the DMSO diffuses under 
aqueous conditions, and thus mechanically occludes the 
vessel19,21-28. The application of the ethylene-vinyl alcohol 
copolymer (EVOH) in the endovascular treatment of in-
tracranial arteriovenous malformations (AVMs) was first 
described by Taki et al.21 and Terada et al.22 in the early 
1990s. The FDA approved the intravascular use of Onyx 
for embolization of intracranial AVMs in July 2005. Since 
that, some series were published reporting the efficacy of 
Onyx® in the management of intracranial AVMs. The ma-
jor advantage to the use of Onyx® compared with cyano-
acrylates is the ease of injection. The catheter should be 
placed in the same wedge situation as for intranidal glue 
injection23,24. The injection should be very slow, as well. It 
may be stopped for a few seconds or minutes to wait for 
precipitation of Onyx® in order to avoid reflux, and then 
resumed. Control angiography may be performed dur-
ing Onyx® injection for a better understanding of mate-
rial progression and of nidus and vein occlusion. Onyx® 
always behaves as a column, and the formation of small 
drops flowing into the vein that may be seen when glue 
is injected too fast, normally do not occur. The injection 
may last for several minutes or even tens of minutes23,24. 
The total amount of Onyx® injected at one time in one 
single pedicle may therefore be much more than with 
glue. It reduces the number of catheters used and the to-
tal number of procedures needed to achieve a complete 
cure of the AVM23. The other major advantage is that in-
jection is more prolonged and the decision to stop or con-
tinue the injection does not have to be made immediate-
ly, as it does for glue injection. 
DAVF closure with Onyx® was first reported by Rezende 
et al.25 in 2006, in a patient with a lesser sphenoid wing re-
gion fistula with direct cortical venous drainage. After that, 
few other reports and case series were published19,26-28.
Cognard et al.19 presented a series of 30 patients with 
DAVFs, 20 of those with direct cortical venous drainage. 
Complete cure was achieved in 23 (92%) of 25 patients 
who were not previously treated, with no recidive on fol-
low-up. It took only 1 procedure for 20 patients. One pa-
tient with tentorial DAVF presented with ophtalmople-
gia and facial pain after partial embolization due to fora-
men spinosum Onyx® reflux and rebled 2 years later. An-
other patient with tentorial DAVF had a cerebellar syn-
drome and hemorrhage after treatment secondary to ex-
tensive thrombosis of the draining vein. Nogueira et al.27 
reported 91.7% rate of cure in a 12 patient series with no 
significant morbidity or mortality. Ten of those had direct 
cortical venous drainage. They had 1 (11%) recidive in 9 
patients followed-up angiographically.
Similarly to the mentioned series above, we achieved 
complete occlusion of the fistula in all patients solely with 
Onyx®. Only one procedure and injection in only one 
pedicle (middle meningeal artery or anterior ethmoidal 
artery) was sufficient to close the fistula in these patients. 
Additionally, we had no complications and no patient de-
teriorated after treatment. All patients improved or had 
their symptoms resolved. One case at our series present-
ed very tortuous feeders. It was not possible to navigate 
the microcatheter to reach a satisfactory position to inject 
Onyx. Based on previous reports, we decided to perform 
a small craniectomy to obtain access to the middle men-
ingeal artery29. We recognize that on these situations, a 
direct surgical approach could be an alternative. 
Our series included only dural arteriovenous fistulas 
with direct cortical venous drainage (without venous si-
nus involvement) treated with Onyx®. We achieved a high 
rate of cure following some steps: [1] performing detailed 
angiographic study of the fistula (feeding artery, fistula 
point and draining vein well visualized), [2] selecting only 
dural arteriovenous fistulas with direct cortical venous 
drainage, [3] performing embolizations via a meningeal 
branch, [4] trying to reach the fistulous zone as close as 
possible or at least wedged into position, [5] performing 
very slow, intermittent injections, resulting in enhanced 
penetration into the fistula point and [6] avoiding reflux 
toward cranial base foramina. These points are critical for 
successful embolization. 
Based on these findings, Onyx® showed to be effec-
tive and safe. While it allows a prolonged time of larger 
volume injections and predictable effect, its penetration 
reaches the feeding vessel more distally, occluding the exit 
vein and other feeders retrogradely. Despite its advantag-
es, adverse effects may happen, such as catheter rupture 
or entrapment, angiotoxity and undesired reflux23,24.
According to Cognard et al.19, Onyx® injections were 
easier to control than NBCA injections. A much larger 
volume could be injected over a longer time period. In-
jection in a single feeder allowed obtaining arterioarterial 
reflux and avoided embolization of other feeders. Access 
through the meningeal artery was more efficient even if the 
size was very small. They suggested that Onyx can be used 
as a primary treatment option for most cases of DAVFs 
with direct CVR. Nogueira et al.27 described that Onyx® 
appears to allow for embolization from more proximal 
locations than cyanoacrylate. This may be accomplished 
without compromising the Onyx® penetration into the fis-
tula. They have used this technique in cases where unfa-
vorable vascular anatomy prevents more distal microcath-
eterization. Another potential advantage of Onyx® over cy-
anoacrylate is that Onyx embolization may allow for the 
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occlusion of several different vessel feeders from a single 
pedicle. This avoids the time and repeated risk of subse-
quent catheterizations that may be required with NBCA.
For DAVFs with direct CVR (type III-IV) the transar-
terial approach with Onyx® is a new option. 
In conclusion, we consider Onyx® a promising option 
in the management of dural arteriovenous fistulas with 
direct cortical venous drainage. It showed to be feasible, 
safe and effective. Long term follow-up and comparative 
studies are necessary to allow drawing conclusions on the 
superiority of this technique.
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